Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data:

Background:Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from follow-up periods longer th...